Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine): Use in elderly

Due to progressive deterioration in renal function, elderly patients may require a reduction in insulin dose.

Detailed information

In elderly patients, 65 years of age or older, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.1-3

Caution should be exercised when Abasaglar is administered to elderly patients.4

In elderly patients with DM, the warning symptoms of hypoglycemia may be altered due to impaired counterregulatory hormonal responses. Elderly patients may be more prone to severe hypoglycemia due to a disconnect between the onset of hypoglycemic symptoms and cognitive dysfunction.2

Abasaglar Phase 3 Studies

In the Abasaglar phase 3 studies in patients with T1DM or T2DM, the safety outcomes that were evaluated for possible subgroup differences in response to study drug included the

  • TEAEs, overall incidence and preferred terms with >5% incidence (nasopharyngitis and upper respiratory tract infection)

  • overall incidence of allergic events from the special topic assessment

  • overall incidence of injection site reactions

  • overall incidence of SAEs, and

  • incidence of TEAR.4

There were no significant treatment-by-entry age interactions for any of the safety outcomes analyzed, indicating no significant differential treatment effects on the safety outcomes across age categories.4

The safety analyses were not performed in patients ≥75 years of age as there were too few of these patients with events of

  • upper respiratory tract infection

  • allergic events

  • injection site reactions

  • SAEs, or

  • TEAR.4

References

1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Ligthelm RJ, Kaiser M, Vora J, Yale JF. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60(8):1564-1570. http://dx.doi.org/10.1111/j.1532-5415.2012.04055.x

3. Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4(4):113-121. http://dx.doi.org/10.1177/2042018813501188

4. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

DM = diabetes mellitus

SAE = serious adverse event

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

TEAE = treatment-emergent adverse event

TEAR = treatment-emergent antibody response

Date of Last Review: October 11, 2018


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question